

Amendments to the Claims

Please amend Claim 27. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

Claims 1-26 (canceled)

Claim 27 (currently amended): A monoclonal antibody detecting and binding monospecifically human Mcm3 both immunohistologically and immunobiochemically, whereby the epitope of the monoclonal antibody of the hybridoma cell line with the deposit number DSM ACC2388 ~~is detected~~.

Claim 28 (canceled)

Claim 29 (previously presented): A monoclonal antibody specific for human Mcm3 which is produced by the hybridoma cell line with the deposit number DSM ACC2388.

Claim 30 (canceled)

Claim 31 (previously presented): A hybridoma cell line which expresses a monoclonal antibody specific for human Mcm3, whereby the hybridoma cell line is the cell line with the deposit number DSM ACC2388.

Claim 32 (previously presented): A method of detecting human Mcm3 using the monoclonal antibody of Claim 27.

Claim 33 (previously presented): A method for the immunohistological, immunocytological or immunobiochemical detection of human Mcm3 in a sample using the monoclonal antibody of Claim 27.

- Claim 34 (previously presented): A method of Claim 33 wherein the sample is selected from serum, sputum, urine, or liquor.
- Claim 35 (previously presented): A method of Claim 33 wherein the sample is tissue or a fine needle aspiration product.
- Claim 36 (previously presented): A method of Claim 33 wherein the method is an immunobiochemical method selected from ELISA, RIA, Western Blot, Far Western Blot, immunoprecipitation and affinity chromatographic steps.
- Claim 37 (previously presented): A method of Claim 33 wherein the method is an immunocytological method selected from FACS and MACS.
- Claim 38 (previously presented): A method of Claim 33 wherein the method is an immunohistological method selected from fluorescence, radioactive, enzymatic and chemiluminescence methods.
- Claims 39-40 (canceled)
- Claim 41 (previously presented): A process for the production of purified human Mcm3, characterized in that the process comprises an affinity chromatography step with a monoclonal antibody according to Claim 27.
- Claim 42 (previously presented): A process for the production of purified human Mcm3 comprising an immunoprecipitation step with a monoclonal antibody according to Claim 27.
- Claims 43-48 (canceled)

- Claim 49 (previously presented): A diagnostic composition comprising a monoclonal antibody according to Claim 27.
- Claim 50 (previously presented): A diagnostic composition comprising a monoclonal antibody according to Claim 29.
- Claim 51 (previously presented): A diagnostic kit comprising the monoclonal antibody according to Claim 27.
- Claim 52 (previously presented): A diagnostic kit according to Claim 51 for the combined detection of the expression of Mcm3, Ki-67 and p27 for tumor diagnosis.
- Claim 53 (previously presented): A diagnostic kit comprising the monoclonal antibody according to Claim 29.
- Claim 54 (previously presented): A diagnostic kit according to Claim 52 for the combined detection of the expression of Mcm3, Ki-67 and p27 for tumor diagnosis.
- Claim 55 (previously presented): A method of detecting human Mcm3 using the monoclonal antibody of Claim 29.
- Claim 56 (previously presented): A method for the immunohistological, immunocytological or immunobiochemical detection of human Mcm3 in a sample using the monoclonal antibody of Claim 29.
- Claim 57 (previously presented): A method of Claim 56 wherein the sample is selected from serum, sputum, urine, or liquor.
- Claim 58 (previously presented): A method of Claim 56 wherein the sample is tissue or a fine needle aspiration product.

- Claim 59 (previously presented): A method of Claim 56 wherein the method is an immunobiochemical method selected from ELISA, RIA, Western Blot, Far Western Blot, immunoprecipitation and affinity chromatographic steps.
- Claim 60 (previously presented): A method of Claim 56 wherein the method is an immunocytological method selected from FACS and MACS.
- Claim 61 (previously presented): A method of Claim 56 wherein the method is an immunohistological method selected from fluorescence, radioactive, enzymatic and chemiluminescence methods.
- Claim 62 (canceled)
- Claim 63 (previously presented): A process for the production of purified human Mcm3, characterized in that the process comprises an affinity chromatography step with a monoclonal antibody according to Claim 29.
- Claim 64 (previously presented): A process for the production of purified human Mcm3, comprising an immunoprecipitation step with a monoclonal antibody according to Claim 29.